Insights on the Worldwide Pulmonary Arterial Hypertension Industry to 2030 - Current Treatment Practices, Emerging Drugs & Market Share of the Individual Therapies - Yahoo Finance

---

Insights on the Worldwide Pulmonary Arterial Hypertension Industry to 2030 - Current Treatment Practices, Emerging Drugs & Market Share of the Individual Therapies - Yahoo Finance Posted: 07 Apr 2020 03:38 AM PDT Dublin, April 07, 2020 (GLOBE NEWSWIRE) -- The "Pulmonary Arterial Hypertension (PAH) - Market Insights, Epidemiology and Market Forecast - 2030" report has been added to ResearchAndMarkets.com's offering. Pulmonary Arterial Hypertension (PAH)- Market Insights, Epidemiology and Market Forecast-2030 report delivers an in-depth understanding of the disease, historical & forecasted epidemiology as well as the market trends of PAH's in the United States, EU5 (Germany, Spain, Italy, France and United Kingdom) and Japan. The Report provides the current treatment practices, emerging drugs, market share of the individual therapies, and current and forecasted market size of Pulmonary Arterial Hypertension (PAH) from 2017 to 2030 segmented by seven major markets. The Report also covers current treatment practice/algorithm, market drivers, market barriers and unmet medical needs to curate best of the opportunities and assess underlying potential of the market. Key Benefits This report will help to develop Business Strategies by understanding the trends shaping and driving Pulmonary Arterial Hypertension market Organize sales and marketing efforts by identifying the best opportunities for Pulmonary Arterial Hypertension market To understand the future market competition in the Pulmonary Arterial Hypertension market. Pulmonary Arterial Hypertension (PAH) - Disease Understanding and Treatment Algorithm Pulmonary Arterial Hypertension (PAH) is a rare, chronic, and progressive form of Pulmonary Hypertension which is characterized by the elevated pulmonary arterial pressure (PAP) and pulmonary vascular resistance (PVR) in blood vessels carrying the blood from the right side of the heart through lungs. It occurs due to the tightening and stiffening of the small pulmonary arteries leading to the right ventricular dysfunction and vessel obstruction. The Pulmonary Arterial Hypertension (PAH) market report gives the thorough understanding of the PAH by including details such as disease definition, classification, symptoms, etiology, pathophysiology, diagnostic trends. It also provides treatment algorithms and treatment guidelines for Pulmonary Arterial Hypertension in the US, Europe and Japan. Pulmonary Arterial Hypertension Epidemiology The Pulmonary Arterial Hypertension (PAH) epidemiology division provide the insights about historical and current patient pool and forecasted trend for every 7 major countries. It helps to recognize the causes of current and forecasted trends by exploring numerous studies and views of key opinion leaders. This part of The report also provides the diagnosed patient pool and their trends along with assumptions undertaken. The disease epidemiology covered in the report provides historical as well as forecasted epidemiology (total prevalent population of PAH, subtype-specific population of PAH and gender-specific PAH diagnosed pool) scenario of Pulmonary Arterial Hypertension (PAH) in the 7MM covering United States, EU5 countries (Germany, Spain, Italy, France and United Kingdom) and Japan from 2017-2030. According to the publisher, the total number of prevalent cases of Pulmonary Arterial Hypertension (PAH) in 7MM was found to be 70,774, in the year 2017. Pulmonary Arterial Hypertension Drug Chapters This segment of the Pulmonary Arterial Hypertension report encloses the detailed analysis of marketed drugs and late stage (Phase-III and Phase-II) pipeline drugs. It also helps to understand the clinical trial details, expressive pharmacological action, agreements and collaborations, approval and patent details, advantages and disadvantages of each included drug and the latest news and press releases. The therapeutic market of Pulmonary Arterial Hypertension is driven by the use of endothelin receptor antagonists, prostanoids, and phosphodiesterase inhibitors for the treatment of Pulmonary Arterial Hypertension. Among these therapeutics endothelin receptor antagonists are most widely used for the treatment of PAH. Letairis\Volibris (GlaxoSmithKline plc\Gilead Science), Opsumit (Actelion Pharmaceuticals Ltd), and Tracleer (Actelion Pharmaceuticals Ltd) are mostly recommended endothelin receptor antagonists being used for the treatment of Pulmonary Arterial Hypertension. These antagonists act by relaxing blood vessels and inhibiting proliferation and remodeling of blood vessels. Pulmonary Arterial Hypertension Market Outlook The Pulmonary Arterial Hypertension market outlook of the report helps to build the detailed comprehension of the historic, current and forecasted trend of the market by analyzing the impact of current therapies on the market, unmet needs, drivers and barriers and demand of better technology. This segment gives a through detail of market trend of each marketed drug and late-stage pipeline therapy by evaluating their impact based on annual cost of therapy, inclusion and exclusion criteria's, mechanism of action, compliance rate, growing need of the market, increasing patient pool, covered patient segment, expected launch year, competition with other therapies, brand value, their impact on the market and view of the key opinion leaders. The calculated market data are presented with relevant tables and graphs to give a clear view of the market at first sight. According to the publisher, the market of Pulmonary Arterial Hypertension in 7MM was found to be USD 4.6 Billion in 2017, and is expected to increase during the course of the study period (2017-2030). Among the 7MM, the United States accounts for the largest market size of PAH, in comparison to EU5 (the United Kingdom, Germany, Italy, France, and Spain) and Japan. Pulmonary Arterial Hypertension Drugs Uptake This section focusses on the rate of uptake of the potential drugs recently launched in the market or will get launched in the market during the study period from 2017-2030. The analysis covers market uptake by drugs; patient uptake by therapies and sales of each drug. This helps in understanding the drugs with the most rapid uptake, reasons behind the maximal use of new drugs and allows the comparison of the drugs on the basis of market share and size which again will be useful in investigating factors important in market uptake and in making financial and regulatory decisions. Pulmonary Arterial Hypertension Report Insights Patient Population Therapeutic Approaches Pipeline Analysis Market Size and Trends Market Opportunities Impact of upcoming Therapies Pulmonary Arterial Hypertension Report Key Strengths 11 Year Forecast 7MM Coverage Epidemiology Segmentation Drugs Uptake Highly Analyzed Market Key Cross Competition Pulmonary Arterial Hypertension Report Assessment Current Treatment Practices Unmet Needs Detailed Pipeline Product Profiles Market Attractiveness Market Drivers and Barriers Key Topics Covered: 1. Key Insights 2. Executive Summary of Pulmonary Arterial Hypertension 3. SWOT Analysis for Pulmonary Arterial Hypertension 4. Pulmonary Arterial Hypertension (PAH) Market Overview at a Glance 4.1. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2017 4.2. Market Share (%) Distribution of Pulmonary Arterial Hypertension (PAH) in 2030 5. Disease Background and Overview: Pulmonary Arterial Hypertension (PAH) 5.1. Introduction 5.2. Signs and Symptoms 5.3. Classification of Pulmonary Arterial Hypertension (PAH) 5.3.1. WHO classification 5.3.2. Functional Classification of PAH 5.4. Etiology 5.5. Risk factors 5.6. Pathophysiology 5.7. Diagnosis 5.7.1. Diagnostic Guidelines: European Guidelines of PAH 6. Epidemiology and Patient Population 6.1. Key Findings 6.2. Population and Forecast Parameters 6.3. 7MM Total Prevalent Patient Population of Pulmonary Arterial Hypertension [PAH] 7. Country Wise-Epidemiology of Pulmonary Arterial Hypertension (PAH) 7.1. The United States 7.1.1. Total Prevalent Patient Population of PAH in the United States 7.1.2. Sub-type Specific Prevalence of PAH in the United States 7.1.3. Gender specific Prevalence of PAH in the United States 7.2. Germany 7.2.1. Total Prevalent Patient Population of PAH in Germany 7.2.2. Sub-type Specific Prevalence of PAH in Germany 7.2.3. Gender specific Prevalence of PAH in Germany 7.3. France 7.3.1. Total Prevalent Patient Population of PAH in France 7.3.2. Sub-type Specific Prevalence of PAH in France 7.3.3. Gender specific Prevalence of PAH in France 7.4. Italy 7.4.1. Total Prevalent Patient Population of PAH in Italy 7.4.2. Sub-type Specific Prevalence of PAH in Italy 7.4.3. Gender specific Prevalence of PAH in Italy 7.5. Spain 7.5.1. Total Prevalent Patient Population of PAH in Spain 7.5.2. Sub-type Specific Prevalence of PAH in Spain 7.5.3. Gender specific Prevalence of PAH in Spain 7.6. The United Kingdom 7.6.1. Total Prevalent Patient Population of PAH in the UK 7.6.2. Sub-type Specific Prevalence of PAH in the UK 7.6.3. Gender specific Prevalence of PAH in the United Kingdom 7.7. Japan 7.7.1. Total Prevalent Patient Population of PAH in Japan 7.7.2. Sub-type Specific Prevalence of PAH in Japan 7.7.3. Gender specific Prevalence of PAH in Japan 8. Treatment Algorithm 8.1. Current Treatment Practices 8.2. Treatment Guidelines 8.2.1. CHEST Guidelines [The United States] 8.2.2. European Society of Cardiology (ESC) and of the European Respiratory Society (ERS) Guidelines 9. Unmet Needs 10. Case Studies 10.1. A Rare Case of Drug Induced PAH 10.2. A Case Report of Unconventional Delivery of Inhaled NO 11. Organizations related with PAH 12. Marketed Drugs 12.1. Approval and Market Presence 13. Marketed Drugs by Companies 13.1. United Therapeutics Corporation 13.2. Johnson & Johnson 13.3. GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc. 13.4. Bayer AG 13.5. Pfizer 14. Safety and Efficacy of Marketed Drugs 15. Emerging Therapies 15.1. Emerging Drugs Analysis 15.2. Aurora-GT: United Therapeutics 15.2.1. Other Developmental Activities 15.2.2. Clinical Development 15.2.3. Safety and Efficacy 15.3. Ralinepag: United Therapeutics 15.3.1. Other Developmental Activities 15.3.2. Clinical Development 15.3.3. Safety and Efficacy 15.4. Liquidia Technologies 15.4.1. Other Developmental Activities 15.4.2. Clinical Development 15.4.3. Safety and Efficacy 15.5. Bardoxolone Methyl: Reata Pharmaceuticals 15.5.1. Other Developmental Activities 15.5.2. Clinical Development 15.5.3. Safety and Efficacy 15.6. Rodatristat Ethyl: Altavant Sciences 15.6.1. Other Development Activities 15.6.2. Clinical Development 15.6.3. Safety and Efficacy 15.7. Sotatercept: Acceleron Pharma 15.7.1. Other Developmental Activities 15.7.2. Clinical Development 15.7.3. Safety and Efficacy 15.8. PB1064: PhaseBio Pharmaceuticals 15.8.1. Other Developmental Activities 15.8.2. Clinical Development 15.8.3. Safety and Efficacy 15.9. CXA-10: Complexa 15.9.1. Other Developmental Activities 15.9.2. Clinical Development 15.9.3. Safety and Efficacy 16. Other Promising Candidates 16.1. Inhaled Nitric Oxide: Bellerophon Pulse Technologies 16.1.1. Other Developmental Activities 16.1.2. Clinical Development 16.1.3. Safety and Efficacy 16.2. RT234: Respira Therapeutics 16.2.1. Other Developmental Activities 16.2.2. Clinical Development 16.2.3. Safety and Efficacy 17. Pulmonary Arterial Hypertension (PAH): 7 Major Market Analysis 17.1. Key Findings 17.2. Total Market Size of PAH in 7MM 17.3. Market Outlook: 7MM 18. United States 18.1. Total Market size of PAH 18.2. PAH Market Size by Therapies 19. EU5 Countries 19.1. Germany 19.1.1. Total Market size of PAH 19.1.2. PAH Market Size by Therapies 19.2. France 19.2.1. Total Market size of PAH 19.2.2. PAH Market Size by Therapies 19.3. Italy 19.3.1. Total Market size of PAH 19.3.2. PAH Market Size by Therapies 19.4. Spain 19.4.1. Total Market size of PAH 19.4.2. PAH Market Size by Therapies 19.5. United Kingdom 19.5.1. Total Market size of PAH 19.5.2. PAH Market Size by Therapies 20. Japan 20.1. Total Market size of PAH 20.2. PAH Market Size by Therapies 21. Market Drivers 22. Market Barriers 23. Appendix 23.1. Bibliography 23.2. Report Methodology 24. Capabilities 25. Disclaimer 26. About the Publisher Companies Mentioned United Therapeutics Corporation Johnson & Johnson GlaxoSmithKline Pharmaceuticals/Gilead Sciences Inc. Bayer AG Pfizer Liquidia Technologies Reata Pharmaceuticals Altavant Sciences Acceleron Pharma PhaseBio Pharmaceuticals Complexa Bellerophon Pulse Technologies Respira Therapeutics For more information about this report visit https://www.researchandmarkets.com/r/whz6rk Research and Markets also offers Custom Research services providing focused, comprehensive and tailored research. CONTACT: ResearchAndMarkets.com Laura Wood, Senior Press Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900

I Ditched My Dietary Rules to Embrace Cooking as Therapy - Pulmonary Hypertension News Posted: 06 Apr 2020 01:00 PM PDT I've written before about how I have adjusted my diet since my pulmonary hypertension diagnosis, but this isn't something I've always found easy. When struggling with mental health or the usual pressures of daily life, it can be difficult to find the time and motivation to properly look after yourself.  Realizing that cooking and preparing food isn't merely a means to an end has changed my mindset. In the past six months, I've shifted from an attitude of discipline, where I would scold myself whenever I broke any of my dietary rules (e.g. no salt or processed foods), to one where I focus on enjoying the process of making a healthy meal as a form of therapeutic self-care.  Self-care is a term we hear thrown around often these days but it's not something I'm very good at, and, it turns out, it's more than just applying a facial mask or doodling in an adult coloring book (though there's plenty to be said for those activities). According to Psychcentral, self-care is "any activity that we do deliberately in order to take care of our mental, emotional, and physical health … good self-care is key to improved mood and reduced anxiety." For me, it's been as simple as telling myself that my body deserves to eat well, that my body deserves to be looked after, that my body deserves better than a ready meal. I've found that treating physical self with the care it deserves has a massive effect on mental well-being and sense of self-worth. Furthermore, the physical activity of cooking can be a respite from the anxieties of daily life. When focusing on the task at hand, your mind has to be present. Who knew chopping vegetables could be an act of mindfulness! Mindfulness is another popular term I've only recently come to fully understand. The National Health Service describes it as "paying attention to the present moment — to your own thoughts and feelings, and to the world around you." Mark Williams, former director of the Oxford Mindfulness Centre, says "an important part of mindfulness is reconnecting with our bodies and the sensations they experience. This means waking up to the sights, sounds, smells and tastes of the present moment."   So now when I'm making dinner, I will put on some nice music or a podcast, make myself a cup of (decaf) tea and pay attention to the smells, sounds, and tastes of my cooking — all the while knowing that I'm doing something good for my body. By thinking less about a restricted diet plan and more about trying to find new recipes that will nourish my body, I have been able to kill two birds with one stone — caring for my body and my mind in one go. *** Note: Pulmonary Hypertension News is strictly a news and information website about the disease. It does not provide medical advice, diagnosis, or treatment. This content is not intended to be a substitute for professional medical advice, diagnosis, or treatment. Always seek the advice of your physician or other qualified health provider with any questions you may have regarding a medical condition. Never disregard professional medical advice or delay in seeking it because of something you have read on this website. The opinions expressed in this column are not those of Pulmonary Hypertension News or its parent company, BioNews Services, and are intended to spark discussion about issues pertaining to pulmonary hypertension.

You are subscribed to email updates from "pulmonary hypertension diagnosis" - Google News. To stop receiving these emails, you may unsubscribe now.	Email delivery powered by Google
Google, 1600 Amphitheatre Parkway, Mountain View, CA 94043, United States